PAMGENE INTERNATIONAL BV

Their core work

PamGene is a Dutch biotech SME that develops and commercializes peptide microarray technology for profiling kinase activity in biological samples. Their platform enables researchers and pharma companies to measure cellular signaling pathways, making it a key tool for drug development, toxicology screening, and disease mechanism studies. In H2020, they contributed their proprietary assay technology to consortia working on melanoma therapies, eye disease translational medicine, and endocrine disruptor testing — always as the technology provider enabling other partners' research.

What they specialise in

How they've shifted over time

PamGene's H2020 trajectory shows a shift from therapeutic disease research toward regulatory toxicology and safety testing. Their earlier projects (2016-2017) focused on disease-specific applications — melanoma treatment and eye disease translational medicine. By 2019, their most recent project (EDCMET) moved into endocrine disruption and adverse outcome pathway modeling, applying their microarray platform to chemical safety assessment rather than drug discovery. This pivot toward toxicology testing methods represents a broadening of their commercial addressable market.

PamGene is moving from pharma-oriented disease research toward regulatory toxicology and chemical safety testing — a growing market driven by EU chemical regulations like REACH.

How they like to work

PamGene operates exclusively as a specialist participant, never leading consortia but consistently joining as the technology provider that enables other partners' experiments. With 34 unique partners across just 3 projects, they work in large, diverse consortia (averaging 11+ partners per project). This pattern suggests they are valued for a specific, hard-to-replace capability rather than broad project management — a reliable plug-in partner for any consortium needing kinase or signaling pathway profiling.

PamGene has built a wide network of 34 unique partners across 14 countries through just 3 projects, indicating they integrate into large European research consortia. Their geographic spread is notably broad for an SME of their size, reflecting demand for their specialized technology across the continent.

What sets them apart

PamGene occupies a rare niche as a commercial provider of peptide microarray-based kinase profiling — a technology few others offer at this specificity. Their platform is not easily substituted, which explains why diverse consortia across oncology, translational medicine, and toxicology all recruit them. For consortium builders, PamGene brings a turnkey assay capability that can be applied to virtually any project needing cellular signaling analysis, without requiring the consortium to build this capacity in-house.

Highlights from their portfolio

• UM Cure 2020
  Largest single grant (EUR 469,625) and their entry into H2020, applying kinase profiling to develop new uveal melanoma therapies.
• EDCMET
  Most recent project signaling a strategic pivot toward endocrine disruption testing and adverse outcome pathway methods — a growing regulatory field.
• transMed
  MSCA training network participation shows PamGene's role in educating next-generation researchers on their technology platform.